Literature DB >> 26122841

Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.

Zhaoxia Qu1, Fan Sun2, Jingjiao Zhou2, Liwen Li2, Steven D Shapiro3, Gutian Xiao1.   

Abstract

Recent studies suggest that high expression of the proinflammatory cytokine IL6 is associated with poor survival of lung cancer patients. Accordingly, IL6 has been a target of great interest for lung cancer therapy. However, the role of IL6 in lung cancer has not been determined yet. Here, we demonstrate that IL6 plays opposite roles in the initiation and growth of lung cancer in a mouse model of lung cancer induced by the K-Ras oncogene. We find that compared with wild-type mice, IL6-deficient mice developed much more lung tumors after an activating mutant of K-Ras was induced in the lungs. However, lung tumors developed in IL6-deficient mice were significantly smaller. Notably, both the lung tumor-suppressing and -promoting functions of IL6 involve its ability in activating the transcription factor STAT3. IL6/STAT3 signaling suppressed lung cancer initiation through maintaining lung homeostasis, regulating lung macrophages, and activating cytotoxic CD8 T cells under K-Ras oncogenic stress, whereas it promoted lung cancer cell growth through inducing the cell proliferation regulator cyclin D1. These studies reveal a previously unexplored role of IL6/STAT3 signaling in maintaining lung homeostasis and suppressing lung cancer induction. These studies also significantly improve our understanding of lung cancer and provide a molecular basis for designing IL6/STAT3-targeted therapies for this deadliest human cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26122841      PMCID: PMC4537823          DOI: 10.1158/0008-5472.CAN-14-3042

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer.

Authors:  Eitetsu Koh; Toshihiko Iizasa; Haruko Yamaji; Yasuo Sekine; Kenzo Hiroshima; Ichiro Yoshino; Takehiko Fujisawa
Journal:  Int J Surg Pathol       Date:  2012-02-13       Impact factor: 1.271

2.  [Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)].

Authors:  Fang Huang; Xiang-ling Wang; Yan Geng; Miao-xian Li
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2005-07

Review 3.  A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.

Authors:  Trevor J Bayliss; Jeff T Smith; Michael Schuster; Konstantin H Dragnev; James R Rigas
Journal:  Expert Opin Biol Ther       Date:  2011-10-13       Impact factor: 4.388

4.  Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.

Authors:  Chin Hao Chang; Chin Fu Hsiao; Yu Min Yeh; Gee Chen Chang; Ying Huang Tsai; Yuh Min Chen; Ming Shyan Huang; Hui Ling Chen; Yao Jen Li; Pan Chyr Yang; Chien Jen Chen; Chao A Hsiung; Wu Chou Su
Journal:  Int J Cancer       Date:  2012-10-29       Impact factor: 7.396

5.  Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer.

Authors:  Haruko Yamaji; Toshihiko Iizasa; Eitetsu Koh; Makoto Suzuki; Mizuto Otsuji; Hao Chang; Shinichiro Motohashi; Sana Yokoi; Kenzo Hiroshima; Masatoshi Tagawa; Toshinori Nakayama; Takehiko Fujisawa
Journal:  Cancer Immunol Immunother       Date:  2004-06-04       Impact factor: 6.968

Review 6.  Interleukin-6 and its receptor in cancer: implications for translational therapeutics.

Authors:  David S Hong; Laura S Angelo; Razelle Kurzrock
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

7.  C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis.

Authors:  Bo Zhou; Jing Liu; Ze-Mu Wang; Tao Xi
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

8.  The Role of STAT3 in Non-Small Cell Lung Cancer.

Authors:  Daijiro Harada; Nagio Takigawa; Katsuyuki Kiura
Journal:  Cancers (Basel)       Date:  2014-03-26       Impact factor: 6.639

9.  Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer.

Authors:  G E Carpagnano; O Resta; M P Foschino-Barbaro; E Gramiccioni; F Carpagnano
Journal:  Int J Biol Markers       Date:  2002 Apr-Jun       Impact factor: 3.248

10.  Differential roles of STAT3 in the initiation and growth of lung cancer.

Authors:  Jingjiao Zhou; Zhaoxia Qu; Shapei Yan; Fan Sun; Jeffrey A Whitsett; Steven D Shapiro; Gutian Xiao
Journal:  Oncogene       Date:  2014-10-06       Impact factor: 9.867

View more
  38 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.

Authors:  Jingjiao Zhou; Zhaoxia Qu; Fan Sun; Lei Han; Liwen Li; Shapei Yan; Laura P Stabile; Lin-Feng Chen; Jill M Siegfried; Gutian Xiao
Journal:  Cancer Immunol Res       Date:  2017-01-20       Impact factor: 11.151

Review 3.  Kras and Tumor Immunity: Friend or Foe?

Authors:  Jane Cullis; Shipra Das; Dafna Bar-Sagi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

4.  Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.

Authors:  Xiuling Xu; Wenshu Chen; Shuguang Leng; Mabel T Padilla; Bryanna Saxton; Julie Hutt; Mathewos Tessema; Kosuke Kato; Kwang Chul Kim; Steven A Belinsky; Yong Lin
Journal:  Carcinogenesis       Date:  2017-06-01       Impact factor: 4.944

5.  NF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8+ T cells for tumor promotion.

Authors:  Liwen Li; Lei Han; Fan Sun; Jingjiao Zhou; Kim C Ohaegbulam; Xudong Tang; Xingxing Zang; Kris A Steinbrecher; Zhaoxia Qu; Gutian Xiao
Journal:  Oncoimmunology       Date:  2018-02-27       Impact factor: 8.110

Review 6.  Pharmacological and immunological targeting of tumor mesenchymalization.

Authors:  Justin M David; Charli Dominguez; Claudia Palena
Journal:  Pharmacol Ther       Date:  2016-12-01       Impact factor: 12.310

7.  IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.

Authors:  Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Cancer Res       Date:  2016-04-01       Impact factor: 12.701

Review 8.  Inflammation as a driver and vulnerability of KRAS mediated oncogenesis.

Authors:  Shunsuke Kitajima; Rohit Thummalapalli; David A Barbie
Journal:  Semin Cell Dev Biol       Date:  2016-06-11       Impact factor: 7.727

Review 9.  IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.

Authors:  Nese Unver; Florencia McAllister
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-18       Impact factor: 7.638

10.  Murine Bronchoalveolar Lavage.

Authors:  Fan Sun; Gutian Xiao; Zhaoxia Qu
Journal:  Bio Protoc       Date:  2017-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.